13.04.2022

Together with our collaborators at the MDC and FU Berlin, we describe the effectiveness of a combination therapy involving anti-SARS-CoV-2 monoclonal antibodies and dexamethasone for treatment of COVID-19 in two distinct hamster models. Using single-cell transcriptomics, we identified a subpopulation of neutrophils responsive to dexamethasone treatment and characterized the synergistic anti-viral effects of monoclonal antibody and dexamethasone combination therapy.

You find the press release at the Charité-Website.

Wyler, E. et al. (2022). Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics. Molecular therapy : the journal of the American Society of Gene Therapy 30.